medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (3)

Rosacea: a review

Medina VNA, Vega MME, Arenas GR

Language: Spanish
References: 31
Page: 264-272
PDF size: 229.40 Kb.


ABSTRACT

This article explores rosacea, a chronic inflammatory dermatosis, mainly affects the cheeks, nose, chin and forehead. It is characterized by recurrent episodes of transient or persistent erythema, papules, pustules, telangiectasias and phymatous changes. Recent scientific advances have provided a deeper understanding of the roles of innate and adaptive immunities, as well as neurovascular dysregulation, in the pathogenesis of rosacea. This review explores a range of targeted treatment options, from topical therapies to laser treatments, emphasizing the importance of individualized treatment plans. These personalized approaches not only improve patients’ outcomes but also enhance their quality of life. The article highlights the potential of these targeted therapies to offer significant relief and enhance the quality of life for patients.


REFERENCES

  1. Sharma A, Kroumpouzos G, Kassir M, Galadari H, Goren A,Grabbe S y Goldust M, Rosacea management: a comprehensivereview, J Cosmet Dermatol 2022; 21(5):1895-1904. doi: 10.1111/jocd.14816.

  2. Arenas R, Dermatología. Atlas, diagnóstico y tratamiento, 7ª ed.,México, McGraw-Hill Interamericana, 2019, pp. 39-40.

  3. Rainer BM, Kang S y Chien AL, Rosacea: epidemiology, pathogenesis,and treatment, Dermatoendocrinol 2017; 9(1):e1361574.doi: 10.1080/19381980.2017.1361574.

  4. Chang HC, Huang YC, Lien YJ y Chang YS, Association of rosaceawith depression and anxiety: a systematic review andmeta-analysis, J Affect Disord 2022; 299:239-45. doi: 10.1016/j.jad.2021.12.008.

  5. Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, GielerU, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, NastA, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T,Werner RN, Zierhut M y Reinholz M, S2k guideline: Rosacea, JDtsch Dermatol Ges 2022; 20(8):1147-65. doi: 10.1111/ddg.14849.

  6. Two AM, Wu W, Gallo RL y Hata TR, Rosácea. Parte i: Introduction,categorization, histology, pathogenesis, and risk factors,J Am Acad Dermatol 2015; 72(5):749-58; quiz 759-60. doi:10.1016/j.jaad.2014.08.028.

  7. Dai R, Lin B, Zhang X, Lou Y y Xu S, Depression and anxietyin rosacea patients: a systematic review and meta-analysis,Dermatol Ther (Heidelberg) 2021; 11(6):2089-105. doi: 10.1007/s13555-021-00613-w.

  8. Bernal LE, Zarco AP, Campos P y Arenas R, Rosácea infantil,Bol Med Hosp Infant Mex 2019; 76(2):95-9. doi: 10.24875/BMHIM.18000032.

  9. Steinhoff M, Schmelz M y Schauber J, Facial erythema of rosacea:a etiology, different pathophysiologies and treatmentoptions, Acta Derm Venereol 2016; 96(5):579-86. doi: 10.2340/00015555-2335.

  10. Saab R y Hostoffer R, Rosacea with pustules and papules, JOsteopath Med 2023; 31. doi: 10.1515/jom-2023-0052.

  11. Chen C, Wang P, Zhang L, Liu X, Zhang H, Cao Y, Wang X yZeng Q, Exploring the pathogenesis and mechanism-targetedtreatments of rosacea: previous understanding and updates,Biomedicines 2023; 11(8):2153. doi: 10.3390/biomedicines11082153.

  12. Oge LK, Muncie HL y Phillips-Savoy AR, Rosacea: diagnosis andtreatment, Am Fam Physician 2015; 92(3):187-96.

  13. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL,Granstein RD, Kang S, Macsai M, Gold LS y Tan J, Standardmanagement options for rosacea: the 2019 update by the NationalRosacea Society Expert Committee, J Am Acad Dermatol2020; 82(6):1501-10. doi: 10.1016/j.jaad.2020.01.077.

  14. Buddenkotte J y Steinhoff M, Recent advances in understandingand managing rosacea, F1000Res 2018; 7:F1000 FacultyRev-1885. doi: 10.12688/f1000research.16537.1.

  15. Saric-Bosanac S, Clark AK, Sivamani RK y Shi VY, The role ofhypothalamus-pituitary-adrenal (hpa)-like axis in inflammatorypilosebaceous disorders, Dermatol Online J 2020; 26(2):13030/qt8949296f. pmid: 32239884.

  16. Layton AM, Pharmacologic treatments for rosacea, Clin Dermatol2017; 35(2):207-12. doi: 10.1016/j.clindermatol.2016.10.016.

  17. Redd TK y Seitzman GD, Ocular rosacea, Curr Opin Ophthalmol2020; 31(6):503-7. doi: 10.1097/icu.0000000000000706. pmid:33009083.

  18. Tan J, Almeida LM, Bewley A, Cribier B, Dlova NC, Gallo R, KautzG, Mannis M, Oon HH, Rajagopalan M, Steinhoff M, ThiboutotD, Troielli P, Webster G, Wu Y, Van Zuuren EJ y Schaller M, Updatingthe diagnosis, classification and assessment of rosacea:recommendations from the global Rosacea Consensus (Rosco)panel, Br J Dermatol 2017; 176(2):431-8. doi: 10.1111/bjd.15122.

  19. Stefanou E, Gkentsidi T, Spyridis I et al., Dermoscopic spectrumof rosacea, jeadv Clin Pract 2022; 1:38-44. Disponible en:https://doi.org/10.1002/jvc2.6.

  20. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan Jy Thiboutot D, Standard classification and pathophysiology ofrosacea: the 2017 update by the National Rosacea Society ExpertCommittee, J Am Acad Dermatol 2018; 78(1):148-55. doi:10.1016/j.jaad.2017.08.037. Epub: 28 de octubre de 2017. pmid:29089180.

  21. Lee WJ, Jung JM, Lee YJ, Won CH, Chang SE, Choi JH,Moon KC y Lee MW, Histopathological analysis of 226 patientswith rosacea according to rosacea subtype and severity,Am J Dermatopathol 2016; 38(5):347-52. doi: 10.1097/DAD.0000000000000454.

  22. Barco D y Alomar A, Rosácea, Actas Dermosifiliogr 2008;99(4):244-56. Disponible en: https://www.actasdermo.org/esrosacea-articulo-S0001731008746726.

  23. Parapia LA, History of bloodletting by phlebotomy, Br J Haematol2008; 143(4):490-5. doi: 10.1111/j.1365-2141.2008.07361.x.Epub: 6 de septiembre de 2008. pmid: 18783398.

  24. Zhang H, Tang K, Wang Y, Fang R y Sun Q, Rosacea treatment:review and update, Dermatol Ther (Heidelberg) 2021; 11(1):13-24. doi: 10.1007/s13555-020-00461-0.

  25. Cribier B, Rosacea: treatment targets based on new physiopathologydata, Ann Dermatol Venereol 2022; 149(2):99-107. doi:10.1016/j.annder.2021.11.001.

  26. Van Zuuren EJ, Arents BWM, Van der Linden MMD, VermeulenS, Fedorowicz Z y Tan J, Rosacea: new concepts in classificationand treatment, Am J Clin Dermatol 2021; 22(4):457-65. doi:10.1007/s40257-021-00595-7.

  27. Xu B, Xu Z, Ye S, Sun H, Zhao B, Wu N y Wu J, jak1 inhibitorabrocitinib for the treatment of steroid-induced rosacea: caseseries, Front Med (Lausana) 2023; 1(10):1239869. doi: 10.3389/fmed.2023.1239869.

  28. Saal RC, Borda LJ, Hoffman ML, Roberts AA y Van Voorhees AS,Treatment of granulomatous rosacea with adalimumab, jaadCase Rep 2023; 40:89-91. doi: 10.1016/j.jdcr.2023.08.017. pmid:37771357; pmcid: pmc10523424.

  29. Yang F, Zhang Q, Song D, Liu X, Wang L y Jiang X, A crosssectionalstudy on the relationship between rosacea severityand quality of life or psychological state, Clin Cosmet InvestigDermatol 2022; 15:2807-16. Doi: 10.2147/CCID.S390921.

  30. Bolognia JL, Schaffer JV y Cerroni L (eds.), Dermatology, 5ª ed.,Elsevier, 2024.

  31. Ahn CS y Huang WW, Rosacea pathogenesis, Dermatol Clin2018; 36(2):81-6. doi: 10.1016/j.det.2017.11.001. Epub: 15 de diciembrede 2017. pmid: 29499802.




2020     |     www.medigraphic.com